Joining the conversation are Serge Perras of Abarca Health; Ton Roelandse with Trexin Consulting; and Bertil Chappuis of Xtillion.
In an interview, Abarca Chief Information Officer Serge Perras discussed how Abarca is implementing AI and where he sees the most value for PBMs.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
A judge recently blocked an Arkansas law that would have banned PBMs from owning and operating pharmacies in the state. Although the state plans to appeal, one expert says the law likely has no future.
In an interview, CEO and Founder Chris Crawford talked about the prescription drug cost challenges employers face and how his business can help them save money.
Regulators will have their work cut out for them under a new administration that has expressed an anti-regulatory preference. Republicans next year will control the White House, Senate and House. What will it all mean for pharmacy leaders?
Dan Reedy, senior director of pricing and underwriting for Abarca, spoke recently with MedCity News about what payers should consider as they explore new models and press for greater transparency.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
Season 2 of the MedCity Pivot Podcast has launched with a special focus on the evolution of pharmacy and pharmacy benefit management. The first guest this season is A.J. Loiacono, who leads Capital Rx.
Kevin Sayer would love to bring his company's Dexcom G7 continuous glucose monitor to more people and more quickly. But despite being CEO of a successful device company, he feels frustrated from time to time about how and what the U.S. health system will pay for.
Javier Gonzalez, Chief Growth and Commercial Officer at Abarca, about why payers are increasingly looking for alternatives to the traditional PBM model.
Proposals targeting misaligned financial incentives, price transparency, and pharmacy access are important and necessary reforms. But the consequences of failing to address pharmacy benefit managers’ use of market power to block competition and extract monopoly profits from payers and consumers will not be limited to drug costs – it will change all of healthcare for generations.
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
In this month's episode, we dive into some of the recent executive appointments occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Danny Sanchez, who recently became the new CEO of EmpiRx Health, a value-based pharmacy benefit manager.
There is a huge opportunity for PBMs and health systems to use AI to help address the challenges surrounding the affordability and accessibility of medicines, from navigating formularies to resolving prior authorization. More automation in pharmacies and with ordering workflows is one piece of that puzzle.
For the first time ever, CMS is preparing to negotiate prices for drugs paid for by Medicare. This has sparked a huge debate — will the creation of this taxpayer-funded drug negotiation infrastructure be a failed experiment, or will it become the standard for the future of drug pricing in this country? Jason Borschow, president and CEO of Abarca Health, says it's the latter.
Requiring that PBMs bid on a per member per month guarantee would reduce the employer’s uncertainty by securing the actual per member per month cost to the employer.
A trade association for PBMs says that state PBM regulations in Oklahoma are preempted by federal ERISA and Medicare regulations.